MIRA Pharmaceuticals, Inc. Common Stock (MIRA) - Net Assets
Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has net assets worth $7.55 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.63 Million) and total liabilities ($83.93K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MIRA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.55 Million |
| % of Total Assets | 98.9% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 38.33 |
MIRA Pharmaceuticals, Inc. Common Stock - Net Assets Trend (2020–2024)
This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See MIRA Pharmaceuticals, Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for MIRA Pharmaceuticals, Inc. Common Stock (2020–2024)
The table below shows the annual net assets of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2024. For live valuation and market cap data, see how much is MIRA Pharmaceuticals, Inc. Common Stock worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.20 Million | -49.71% |
| 2023-12-31 | $4.37 Million | +833.67% |
| 2022-12-31 | $-596.23K | -126.37% |
| 2021-12-31 | $2.26 Million | +3425.87% |
| 2020-12-31 | $-67.99K | -- |
Equity Component Analysis
This analysis shows how different components contribute to MIRA Pharmaceuticals, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2906972800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.66K | 0.08% |
| Other Components | $31.34 Million | 1424.52% |
| Total Equity | $2.20 Million | 100.00% |
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of MIRA Pharmaceuticals, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lokotech Group AS
OL:LOKO
|
$40.97 Million |
|
Firetail Resources Ltd
AU:FTL
|
$40.98 Million |
|
Samhwa Networks Co. Ltd
KQ:046390
|
$41.00 Million |
|
Kriti Industries (India) Limited
NSE:KRITI
|
$41.01 Million |
|
Connexa Sports Technologies Inc.
NASDAQ:YYAI
|
$40.96 Million |
|
Orient Paper & Industries Limited
NSE:ORIENTPPR
|
$40.96 Million |
|
SIFCO Industries Inc
NYSE MKT:SIF
|
$40.95 Million |
|
Juic International
TWO:6114
|
$40.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MIRA Pharmaceuticals, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,374,346 to 2,199,750, a change of -2,174,596 (-49.7%).
- Net loss of 7,852,659 reduced equity.
- New share issuances of 3,608,555 increased equity.
- Other factors increased equity by 2,069,508.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.85 Million | -356.98% |
| Share Issuances | $3.61 Million | +164.04% |
| Other Changes | $2.07 Million | +94.08% |
| Total Change | $- | -49.71% |
Book Value vs Market Value Analysis
This analysis compares MIRA Pharmaceuticals, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $0.98 | x |
| 2021-12-31 | $0.15 | $0.98 | x |
| 2022-12-31 | $-0.04 | $0.98 | x |
| 2023-12-31 | $0.24 | $0.98 | x |
| 2024-12-31 | $0.14 | $0.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MIRA Pharmaceuticals, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -356.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.33x
- Recent ROE (-356.98%) is below the historical average (-145.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-61.19K |
| 2021 | -96.25% | 0.00% | 0.00x | 1.48x | $-2.40 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.00 Million |
| 2023 | -273.92% | 0.00% | 0.00x | 1.13x | $-12.42 Million |
| 2024 | -356.98% | 0.00% | 0.00x | 1.33x | $-8.07 Million |
Industry Comparison
This section compares MIRA Pharmaceuticals, Inc. Common Stock's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $7,856,844,400
- Average return on equity (ROE) among peers: 37.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MIRA Pharmaceuticals, Inc. Common Stock (MIRA) | $7.55 Million | 0.00% | 0.01x | $40.96 Million |
| AbbVie Inc (ABBV) | $3.94 Billion | 130.39% | 12.45x | $356.49 Billion |
| Amgen Inc (AMGN) | $933.70 Million | 38.30% | 0.47x | $184.15 Billion |
| Amarin Corporation PLC (AMRN) | $-88.45 Million | 0.00% | 0.00x | $315.59 Million |
| AstraZeneca PLC (AZN) | $39.17 Billion | 15.20% | 1.58x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $14.04 Billion | 15.34% | 3.32x | $275.88 Billion |
| Biogen Inc (BIIB) | $74.90 Million | -25.50% | 0.15x | $27.74 Billion |
| Bristol-Myers Squibb Company (BMY) | $6.57 Billion | 43.38% | 1.24x | $112.89 Billion |
| Gilead Sciences Inc (GILD) | $297.29 Million | -22.37% | 0.47x | $155.64 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $1.27 Billion | 157.62% | 5.56x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $12.36 Billion | 26.73% | 0.74x | $564.26 Billion |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling tr… Read more